{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:00:59Z","timestamp":1778770859380,"version":"3.51.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Follicular dendritic cell sarcoma (FDCS) is an uncommon low-grade malignant sarcoma. For localized FDCS, surgery is the most commonly recommended therapy option. However, there is no standard treatment protocol for metastatic FDCS. Here, we present a 68-year-old female with primary spleen FDCS who had multiple peritoneal metastases. She was treated with sintilimab (PD-1 inhibitor) plus chemotherapy (epirubicin plus ifosfamide) as first-line treatment achieving partial response (PR) and a relatively long progression-free survival (PFS) of 17 months. This case suggests that PD-1 inhibitor plus chemotherapy as first-line therapy seem to be a promising treatment option for metastatic FDCS.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1228653","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:41:46Z","timestamp":1692963706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Jielang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0126-RS","article-title":"Follicular dendritic cell sarcoma","volume":"141","author":"Chen","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.05.006","article-title":"Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series","volume":"88","author":"Saygin","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/107327481402100405","article-title":"Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment","volume":"21","author":"Dalia","year":"2014","journal-title":"Cancer Control"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20852","article-title":"Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature","volume":"82","author":"Soriano","year":"2007","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653319","article-title":"Unexpected favorable outcome to PD-1 antibody plus lenvatinib in a patient with recurrent intestinal follicular dendritic cell sarcoma: A case report and literature review","volume":"12","author":"Lei","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-218889","article-title":"Follicular dendritic sarcoma masquerading as fibrosing mediastinitis","volume":"2017","author":"Cingam","year":"2017","journal-title":"BMJ Case Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-234363","article-title":"Follicular dendritic cell sarcoma and its response to immune checkpoint inhibitors nivolumab and ipilimumab","volume":"13","author":"Lee","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.816903","article-title":"Response of tonsil follicular dendritic cell sarcoma to multimodal treatment including pembrolizumab: A case report and literature review","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B14","article-title":"A primary lymph node Malignancy with features suggestive of dendritic reticulum cell differentiation. A report of 4 cases","volume":"122","author":"Monda","year":"1986","journal-title":"Am J Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare cancers are not so rare: the rare cancer burden in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur J Cancer"},{"key":"B16","article-title":"Follicular dendritic cell tumor: review of the entity","volume":"15","author":"Perez-Ordo\u00f1ez","year":"1998","journal-title":"Semin Diagn Pathol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2007.06.003","article-title":"Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases","volume":"65","author":"De Pas","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24115","article-title":"Follicular dendritic cell sarcoma of the head and neck: Case report, literature review, and pooled analysis of 97 cases","author":"Pang","year":"2016","journal-title":"Head Neck"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14672","article-title":"Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma","volume":"178","author":"Jain","year":"2017","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000590","article-title":"Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders","volume":"40","author":"Xu","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2016.05.003","article-title":"Follicular dendritic cell sarcoma: clinicopathologic study of 15 cases with emphasis on novel expression of MDM2, somatostatin receptor 2A, and PD-L1","volume":"23","author":"Agaimy","year":"2016","journal-title":"Ann Diagn Pathol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/pin.13044","article-title":"Histiocytic and dendritic cell neoplasms: Reappraisal of a Japanese series based on t(14;18) and neoplastic PD-L1 expression","volume":"71","author":"Okada","year":"2021","journal-title":"Pathol Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-16-0301","article-title":"Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of follicular dendritic cell sarcomas","volume":"15","author":"Laginestra","year":"2017","journal-title":"Mol Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1356144","article-title":"Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients","volume":"7","author":"Xing","year":"2018","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201847659","article-title":"Targeting Treg cells in cancer immunotherapy","volume":"49","author":"Tanaka","year":"2019","journal-title":"Eur J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.04.010","article-title":"Progress in tumor-associated macrophage (TAM)-targeted therapeutics","volume":"114","author":"Ngambenjawong","year":"2017","journal-title":"Adv Drug Delivery Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1312","article-title":"Paradigms on immunotherapy combinations with chemotherapy","volume":"11","author":"Salas-Benito","year":"2021","journal-title":"Cancer Discovery"},{"key":"B36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","article-title":"Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy","volume":"452","author":"Yu","year":"2019","journal-title":"Cancer Lett"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1228653\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:41:49Z","timestamp":1692963709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1228653\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2023.1228653"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1228653","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"article-number":"1228653"}}